Pluristem and Abu Dhabi Stem Cells Center Sign MOU to Collaborate in the Development of Cell Therapies and Regenerative Medicines for the Treatment of Severe Diseases Including COVID-19
17 août 2020 02h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
Pluristem Expands its COVID-19 Program to Europe, Receives PEI Clearance to Commence Phase II Study in Germany
10 août 2020 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
Pluristem CEO Issues Shareholder Update on Clinical Programs
21 juil. 2020 07h10 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, July 21, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
Pluristem Announces Activation of Clinical Sites and Commencement of Patient Enrollment in U.S. FDA Phase II COVID-19 ARDS Trial
11 juin 2020 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, June 11, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
Pluristem Joins Forces with CRISPR-IL National Consortium to Advance Development of Cutting-Edge Genome Editing Solutions for Life Science Products
03 juin 2020 07h00 HE
|
Pluristem Therapeutics, Inc.
Collaboration will enable Pluristem to develop new technologies relying on its PLX platformThe consortium is supported by the Israeli Innovation Authority as part of its Bio-Convergence Program, and...
Pluristem Provides 28-Day Follow Up for Ventilator-Dependent COVID-19 Patients under Compassionate Use Program in Israel and U.S.
14 mai 2020 08h00 HE
|
Pluristem Therapeutics, Inc.
87.5% survival rate of patients on invasive mechanical ventilation injected with PLX cells75% of patients no longer in need of any mechanical ventilation 62.5% of the patients discharged alive from...
U.S. FDA Clears Pluristem’s IND Application for Phase II COVID-19 Study
08 mai 2020 06h00 HE
|
Pluristem Therapeutics, Inc.
140 patients with severe COVID-19 and ARDS to be treatedPrimary endpoint: ventilator free days during the main 28-day study period, secondary endpoint includes survival rate and ICU free days HAIFA,...
Pluristem Announces Pricing of Its Registered Direct Offering for Aggregate Proceeds of $15 Million
05 mai 2020 09h56 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, May 05, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
Pluristem Recaps Investor & Analyst Call Reviewing European Investment Bank’s €50 Million Financing
30 avr. 2020 09h30 HE
|
Pluristem Therapeutics, Inc.
• Elaborating on agreement terms and tranches schedule• Provides update on cash position and clinical program HAIFA, Israel, April 30, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc....
EIB signs collaboration with Israel Innovation Authority and €50 million financing agreement with Pluristem to develop therapies for COVID-19 and other unmet medical needs
30 avr. 2020 02h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, April 30, 2020 (GLOBE NEWSWIRE) -- European Investment Bank (EIB) backs Pluristem with €50 million of financing, which will help the company to advance the clinical...